Linklaters announce a significant expansion of its Greater China corporate and capital markets practices with the addition of: Christine Xu as partner and Head of Greater...
You must be a Standard 1 Year member to access this content.
Clifford Chance advised MicroPort Scientific Corporation on the deal. MicroPort Scientific Corporation, a global medical devices company listed on the Hong Kong Stock Exchange (HKEX), has...
You must be a Standard 1 Year member to access this content.
Clifford Chance advises Red Star Macalline Holding on the RMB6.3 billion sale of a 29.95% equity interest in Red Star Macalline Group Corporation to Xiamen C&D....
You must be a Standard 1 Year member to access this content.
Clifford Chance advised JF Wealth on the deal. The transaction involved JF Wealth’s US$142 million initial public offering and listing on the mainboard of the Hong Kong...
You must be a Standard 1 Year member to access this content.
Maples and Calder, together with Skadden, acted for Kanzhun Limited. Clifford Chance advised Morgan Stanley and Goldman Sachs. Morgan Stanley and Goldman Sachs agreed for dual...
You must be a Standard 1 Year member to access this content.
Clifford Chance and JunHe advised cosmetics company Shanghai Chicmax Cosmetic Co., Ltd. on the deal. Freshfields Bruckhaus Deringer advised the joint sponsors. Shanghai Chicmax Cosmetic Co.,...
You must be a Standard 1 Year member to access this content.
Maples Group acted as Cayman Islands legal counsel, Cleary Gottlieb Steen & Hamilton acted as legal advisors to OCFT as to Hong Kong and US laws...
You must be a Standard 1 Year member to access this content.
Clifford Chance has advised Lepu Biopharma Co., Ltd. on the deal. Herbert Smith Freehills has advised CICC and Morgan Stanley. The Joint Sponsors are CICC and...
You must be a Standard 1 Year member to access this content.
Walkers acted as Cayman Islands counsel to Bilibili Inc. in connection with its US$2.6 billion global offering of 25 million shares on the Main Board of...
You must be a Standard 1 Year member to access this content.
Clifford Chance, Maples and Calder JunHe advised SciClone Pharmaceuticals on its US$281 million initial public offering and listing on the main board of the Hong Kong...
You must be a Standard 1 Year member to access this content.
Clifford Chance has advised the joint sponsors Bank of America, UBS and CLSA, and the underwriters on JD.com’s US$3.87 billion initial public offeringand secondary listing on...
You must be a Standard 1 Year member to access this content.
